Leslie Gautam

Leslie Gautam

Executive Director

New York Office  |   |   212.257.5816

Leslie Gautam is an Executive Director at Torreya. She has more than 11 years of experience advising biopharma Executive Management and Boards of Directors on a broad range of strategic decisions as both a member of the Corporate Management Team and as a financial advisor. With extensive strategic advisory experience across biopharma, Leslie has transaction experience in both clinical and commercial stage companies with a particular focus in specialty therapeutic categories across both pharmacological and digital interventions.

Most recently, Leslie was a senior member of the Healthcare practice at Houlihan Lokey where she provided strategic advice on a variety of biopharma transactions, including: M&A, restructurings, independent Board advice and capital raising. Previously, she was a member of the Business Development teams at both Purdue Pharma and Noven Pharmaceuticals. Before working within the biopharmaceutical industry, she was an Institutional Investor ranked equity research analyst for UBS covering the pharmaceutical sector, including Pfizer, Eli Lilly, Allergan, Valeant, Endo, Teva and Mylan. She started her career in the healthcare investment banking group of BMO Capital Markets, where she worked on a wide range of transactions, including sellside and buyside M&A transactions and debt and equity financings.

Leslie holds a B.S. in Psychobiology and Computer Programming from UCLA and an MBA in Finance from Columbia Business School.

Selected Transactions

Acquisition of Serenity LLC and global rights to Noctiva™
Serenity Pharma LLC
$41 million + milestones and royalties
March 2022
Sale of U.S. and Canadian rights for ELYXYB to
August 2021
Common Sensing
Sale of intellectual property to
Bigfoot Biomedical
June 2021
Nuvation Bio
Advisor to the Special Committee of the Board of Directors in its merger with
$1.5 billion
October 2020